CSL opens a new R&D facility in Waltham, Massachusetts

Market Access
CSL opens a new R&D facility in Waltham, Massachusetts

On March 27th, global biopharma company CSL opened a new R&D facility in Waltham, Massachusetts. The facility, which will be focused on next-generation vaccines, includes a BSL3 laboratory facility: the highest security lab, on a level with the CDC, to study potentially dangerous contagions.

pharmaphorum had a chance to watch the ribbon-cutting ceremony and tour the new facility, including the not-yet-operational, high-security lab – and now we invite Deep Dive readers to come along via this photo essay. Want more background on CSL and the lab opening? Check out our video interview with CSL leadership here.

Ethan Settembre, Vice President, Research, Vaccines Innovation Unit, served as master of ceremonies for the brief presentation. Settembre welcomed the crowd of mostly CSL employees and thanked everyone involved for their work in getting the new factory up and running.

“Today, we celebrate not only our grand opening, but our growing R&D footprint and our progress in innovative vaccine technology that prioritises advancing the next generation of R&D technology,” Settembre said.


• Read the full article in pharmaphorum's Deep Dive digital magazine